1. Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations.
- Author
-
Meric-Bernstam, Funda, Lloyd, Michael, Koc, Soner, Evrard, Yvonne, McShane, Lisa, Lewis, Michael, Evans, Kurt, Li, Dali, Rubinstein, Lawrence, Welm, Alana, Dean, Dennis, Srivastava, Anuj, Grover, Jeffrey, Ha, Min, Chen, Huiqin, Huang, Xuelin, Varadarajan, Kaushik, Wang, Jing, Roth, Jack, Welm, Bryan, Govinden, Ramaswamy, Ding, Li, Kaochar, Salma, Mitsiades, Nicholas, Carvajal-Carmona, Luis, Herylyn, Meenhard, Davies, Michael, Shapiro, Geoffrey, Fields, Ryan, Trevino, Jose, Harrell, Joshua, Doroshow, James, Chuang, Jeffrey, and Moscow, Jeffrey
- Subjects
Humans ,Animals ,Xenograft Model Antitumor Assays ,Neoplasms ,National Cancer Institute (U.S.) ,United States ,Mice ,Antineoplastic Agents ,Consensus - Abstract
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
- Published
- 2024